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The field of nanotechnology research has seen a large growth in the past few 
decades due to the great potential of novel nano-size material for useful applications such 
as drug delivery and medical imaging.  Also, they are a promising platform for the 
detection of terrible diseases such as cancer and atherosclerosis.  Although these 
materials hold great promise, there is very limited understanding about the biological 
effects of these nanoparticles on normal healthy cells, such as vascular smooth muscle 
cells (VSMCs).  The VSMCs are unique cells due to the two distinct phenotype 
characteristics it can express: a contractile and a synthetic phenotype.  Normally, they 
express a contractile phenotype for their primary function of regulating the lumen 
diameter of blood vessels.  They also can express a synthetic phenotype when vascular 
injury occurs.  
In this study, the effects of different size citrate capped gold nanoparticles on the 
mechanical properties of vascular smooth muscle cells subject to mechanical stretching 
was investigated.  The first part of the experiment assessed the cytotoxicity of the 
nanoparticle treatment on the cell.  Next, the assessment of the mechanical properties was 
examined using atomic force microscopy (AFM) for cyto-indentation.  The final part of 
the investigation was immunofluorescence staining to look at the alpha actin within the 
cell for possible phenotypic shift. 
 The study showed the citrate nanoparticles did not have any toxic effects on the 
cells, but the nanoparticle treatment did alter the mechanical properties and phenotypic 
expression of the VSMCs.  Under static condition, the nanoparticle treatment decreased 
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the mechanical properties of the cells.  The size of the nanoparticle also had a decreasing 
elastic modulus effect on the cell.  The VSMCs subjected to mechanical stretching 
exhibited higher elastic modulus compared to the static experimental groups.  The 
nanoparticle treatment also decreased the mechanical properties of the cells.  However, 
the size of the nanoparticle did not have any influence on the decrease of the cells elastic 
modulus unlike the static treated cells.  The mechanical testing condition provided a 
better look at how these particles would affect the cells in vivo.  While the nanoparticles 
are not cytotoxic to the VSMCs, they are altering the mechanical properties and 
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Nanotechnology research, such as development of different nanoparticles for 
therapy and imaging of different diseases have shown many promises, especially with 
possible detection and treatment methods for cancer.  Within the past decade, an 
increasing number of research studies and publications using nanomaterials to treat and 
detect cardiovascular disease, such as atherosclerosis, are emerging.  As with any disease, 
early detection will help aid the process of treatment and prevention of further 
development of the disease, but there is still limited understanding of the total effects of 
these nanoparticles on certain cells within our body.  
The cardiovascular system is a significant area of research for many scientific, 
medical, or engineering disciplines.  The cardiovascular system includes the heart and 
blood vessels that pump and transport different nutrients and waste from one part of the 
body to another.  If the cardiovascular system becomes damaged, the entire body is 
affected.  Cardiovascular disease is the leading cause of death in the United States.   
Many people in the U.S. do not recognize or realize the symptoms and indicators of 
cardiovascular disease; therefore, a lot of cases go undiagnosed until severe treatment is 
needed.  Many cardiovascular diseases affect blood vessels, the major transportation 
pathway for blood through the body.  In particular, atherosclerosis is a particular disease 
that occurs when cholesterol and triglycerides accumulate on the walls of blood vessels.  
Initially, the build-up has limited blood flow effects; however, once the disease 
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progresses, the accumulation begins to seriously constrict the fluid flow, a cascade of 
symptoms that can ultimately cause death occurs.  Nano-technological research is 
emerging to tackle the challenges of atherosclerosis and the effects it has on the body.  
However, there is limited understanding about how these particles interact and affect 
normal cells, such as vascular smooth muscle cells.  This lack of information could be 
dangerous if these nanoparticle interactions yield an adverse response.  Therefore, an in-
depth investigation is required to figure out the interactions between healthy cells and 
these nanoparticle with these nanoparticles, and how these interactions affect the overall 
characteristics, mechanical properties, and/or functions of the cells.  
The purpose of this research is to improve upon the understanding of how these 
new nanomaterials, particularly gold nanoparticles, will affect the vascular smooth 
muscle cells found in blood vessels.  
 
1.2 Research Goal: 
Investigate the influence of different size citrate capped gold nanoparticles on the 
mechanical properties of vascular smooth muscle cells subjected to mechanical 
stretching.  
Aim 1: Evaluate the cytotoxicity of gold nanoparticles on VSMCs 
Aim 2: Evaluate the effects of the size of the nanoparticles on the mechanical 
properties VSMCs 
Aim 3: Evaluate how the nanoparticles influence the phenotype expression by 








In recent decades, the use of nanoparticles, particularly metallic nanoparticles, has 
increased in biomedical research.[1] The small size allows for interaction with DNA, 
proteins, lipids, and other cellular components. Common metallic nanoparticles studied 
include gold, silver, titanium oxide, and iron oxide nanoparticles.[2], [3] Gold nanoparticles 
(AuNPs) possess distinct chemical and physical properties and are one of the most widely 
investigated materials. [3-4]  Gold nanoparticles unique properties include: (a) capable of  
synthesizing in a wide variety of sizes from 1 nm -100 nm, (b) controlled synthesis into 
various shapes such as nanospheres, nanorods, nanocubes, nano shells, etc., (c) large 
surface area to volume ratio, (d) stability over a wide range of temperatures, (e) easily 
functionalized as seen in Figure 2.1 with different conjugates such as thiols, amines, 
DNA, enzymes, antibodies, and some functional polymers.[2] All these properties can be 
readily manipulated depending on the desired application.  Thus, nanoparticles and the 
field of nanomedicine provide a promising platform for various solutions for the 
enhancement of different bioimaging modalities, drug delivery applications, cancer 
diagnosis and treatment, and many other biomedical applications. [4], [6]–[8] However, 
while nanotechnologies have shown great promise in these areas, long-term biological 
effects of the nanoparticle and cellular interaction are not fully understood.  Some studies 
have shown adverse effects due to exposure of certain nanoparticles.[9], [10]  Therefore, 
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there is a need for the investigation of the effects of these gold nanoparticles on cellular 
functions.  Understanding the interaction between the cell and the gold nanoparticle is 
important for safe and effective use of these nanomaterials.  In this review, biomedical 
research using nanoparticles, particularly gold nanoparticles, for drug delivery, imaging 

















Figure 2.1: Multifunctional Gold Nanoparticle.  The following are 
illustrated: the ability to carry one or more therapeutic agents; 
biomolecular targeting through one or more conjugates antibodies or 
other recognition agents; imaging signal amplication, and biobarrier 
avoidance by conjugated with polyethylene glycol (PEG) for avoidance 
of macrophage uptake.[6]  
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2.2 Gold Nanoparticles in Drug Delivery Applications 
 Targeted drug delivery system (TDDS) is among the most important research area 
in biomedical engineering and pharmacology.  The goal of TDDS is to increase the 
concentration of the drug in the tissue of interest to enhance the therapeutic effects while 
leaving the normal, healthy tissue unaffected.  The reasons nanoparticles are being 
researched for drug delivery applications are due to the small size, cellular interaction 
compatibility, large surface to volume ratio, and ease of functionalization of the 
particles.[2], [11], [12]  These unique characteristics of nanoparticles allows large surface 
coverage of a desired drug on particles, via ligands or other biomolecules, that because of 
its size, will have the capability to bypass many bio-barriers in the body, target a 
particular tissue of interest, and reduce overall systemic toxicity.  The incorporation of 
drugs onto the nanoparticle would help improve drug solubility; thereby, offering a more 
regulated drug release with enhanced retention at the target site.[13] One research group 
lead by Niidome has examined one of these challenges.  To bypass the reticuloendothelial 
system (RES), which consists of cells that filter out and destroy bacteria, viruses, and 
other foreign substances, AuNPs were conjugated with thiol-derivative polyethylene 
glycol (PEG-SH).  The study found that this PEG-SH outer coating on the cetyl 
trimethylammonium bromide (CTAB) capped AuNPs could delay RES clearance to the 
liver from 30 minutes to 72 hours in mice models, an approximately 150-fold 
improvement compared to unmodified CTAB capped AuNPs.[14] This controlled delay is 
a significant advancement for drug delivery applications.  The unique properties 
nanoparticles offer enable scientists to research and solve more obstacles, such as how to 
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treat diseases in the brain, which is a significant challenge for many drugs cross the 
blood-brain barrier.[15]  
Gold nanoparticle drug delivery has potential use as a feasible platform for the 
targeting and treatment of many cancers.  Kudgus et al. have shown the utilization of 
Gemcitabine conjugated AuNPs inhibited the growth of Pancreatic Adenocarcinoma.[16] 
Another study successfully delivered Doxorubicin, anti-cancer drug, into the nucleus of 
melanoma cells in mice.[17] Many other drugs, such as Oxaliplatin, Paclitaxel, and 
Cisplatin, conjugated with AuNPs are being researched for different treatments of cancer 
such as melanoma and prostrate cancer.[1], [18]–[20]  
 Another drug delivery application with AuNPs includes loading them with 
biomolecules.  Joshi et al. investigated the utilization of oral and intranasal administration 
of colloidal gold nanoparticles conjugated with insulin to diabetic rats in order to reduce 
blood sugar levels.  The studied reported a significant decrease in blood sugar which was 
comparable with the decrease obtained by subcutaneous insulin injections.[21] Another 
study investigated the potential of AuNPs for vaccine delivery for the hepatitis B virus.  
These Chitosan-6-AuNPs have been studied for their efficiency concerning in vitro and in 
vivo applications.  When delivered intramuscularly to mice, these conjugated AuNPs 
were more efficient than the naked DNA vaccine.  The study also found these particles 
induced cytotoxic T lymphocyte responses at a lower dosage when compared to bare 
DNA.[22]   
 There exist numerous completed and on-going research studies on using 
nanoparticles as a drug delivery vehicle for the treatment of many diseases, such as 
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cancer. AuNPs offer many unique attributes allowing for novel drug delivery strategies to 
be discovered.  The key issue is the engineering of these particles for targeting the 
specific site of interest, optimizing the bioavailability, and reducing any adverse 
response.   
2.3 Gold Nanoparticles in Imaging Enhancement Applications 
 There are many imaging modalities such as X-rays, Computed Tomography (CT), 
Positron Emission Tomography (PET), and Magnetic Resonance Imaging (MRI) used 
daily in clinical settings.  These analytical machines help medical professionals view the 
internal anatomy of a patient to look for abnormalities.  Although these imaging methods 
are beneficial tools, there are still complications and limitations with each of the 
techniques.  For example, iodine and bismuth are used as contrasting agents to address 
contrast resolution problems; however, these contrasting agents have limited circulation 
life due to fast filtration by the kidneys, toxicity of the agents at certain concentrations, 
and the limited control for agent site targeting.  In the past decade, research regarding 
AuNP conjugates as a possible contrast agent for different imaging modalities has been 
explored.   
 One of the most widely used and inexpensive imaging techniques is the X-ray.  
X-rays provide rapid clear results of the interior of a patient’s body.  Because of X-ray 
low radiation doses, they do not provide the high soft tissue contrast that the CT and MRI 
scans offer.  In order to increase x-ray contrast, some studies have explored using AuNPs.  
One study has effectively shown AuNPs were efficient enough to be used as an X-ray 
contrast agent in vivo.  Hainfeld et. al. injected 1.9 nm AuNPs into mice.  The injected 
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mice were x-rayed and blood vessels as fine as 100 µm in diameter could be 
distinguished.  The animal study demonstrated AuNPs are useful x-ray contrasting agents 
that offer novel physical and pharmacokinetic advantages over current standard iodine 
based agents.[23] 
 Gold nanoparticles were also explored for their applications in improving CT and 
MRI imaging techniques.  Kim et. al. performed an in vivo study using Sprague-Dawleys 
rats.   The 20-50 nm diameter PEG coated AuNPs intravenously administered to the rats.  
The CT imaging results of the AuNPs treatment were compared to the current iodine-
based contrast agent, Ultravist.  The study found a greater efficiency in the contrast using 
the AuNPs compared to the Ultravist contrast agent.  The AuNPs also had a improved 
circulation time and no renal toxicity; two limitations of using an iodine based contrast 
agent.[24] Another studied used Gadolinium Chelate coated AuNPs as a possible contrast 
agent for both CT and MRI scans.  They also found that gold nanoparticles was a better 
contrast agent than currently used agents and no undesirable effects were observed during 
the administration of the nanoparticles or 6 weeks following the treatment.[25] 
 The use of AuNPs as a contrast agent in different imaging modalities is a feasible 
possibility for future clinical settings.  However, before AuNP implementation in clinical 
settings, a lot more research has to be performed to study the effects the particles have on 
the human body.  Much of the current investigations focused on the feasibility of AuNPs 
as a contrast agent and the possibility of using the particles as an imaging agent for the 
detection of cancer.[5], [26]–[29] There are also recent studies emerging that involve the use 
of nanoparticles for imaging cardiovascular diseases.[30], [31]  These two focuses of AuNPs 
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will be discussed in more detail in the following sections.  Overall, AuNPs have 
demonstrated their promising use in another biomedical research area.    
2.4 Gold Nanoparticles in Cancer Research 
 Cancer is the third leading cause of death (after heart disease and stroke) in 
developed countries and the second leading cause of death (after heart disease) in the 
United States.[27] According to cancer statistics performed by the American Cancer 
Society in 2010, near 600,000 deaths per year are a direct result from cancer and almost 
1.5 million new cancer cases are diagnosed yearly in the U.S. alone.[32] The highest 
survival chance for patients diagnosed with cancer relies on early detection and 
prevention methods.  The unique properties of AuNPs offer various advantages that are 
currently being studied to assist with cancer detection, treatment, and prevention. 
 There are many different studies investigating the effects of AuNPs on different 
types of cancer, see Table 2.1.  These experiments all demonstrate the plausible 
applications of AuNPs for cancer diagnosis and treatment. For instance, Wang et. al. used 
acetylated dendrimer-entrapped gold nanoparticles (ADENPs-AuNPs) for the imaging of 
human lung adencarinoma cell lines in vitro and in vivo.  The results showed the ADENs-
AuNPs were able to assist in the detection of the prescence of cancer cells using CT 
scans.  The study also indicated no sign of cytotoxicity due to the AuNPs at the 
concentration used in the study.[29]   
 Besides just detecting the presence of cancer cells, researchers are hoping to use 
AuNPs as a therapeutic agent to treat cancer tumors.  Researchers at the Mayo Clinic 
looked at the effects of Gemcitabine conjugated AuNPs on the growth of pancreatic 
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adenocarcinoma in vitro and in vivo.  The study found that these particles were effective 
in inhibiting the growth of the tumor in advance stage models.  Further research is being 
conducted to improve the efficacy of the nanosystem and gain greater understanding 
about the pharmacokinetics.[16] However, not all the studies have shown promising 
results.  One studied looked at 5nm diameter Gadolinium conjugated AuNPs effects on 
MC7 breast cancer cells.  The in vitro study showed promising results with a cytotoxic 
effect of up to 55% on the cancer cells.  However, the in vivo studied showed no 
significant difference between the treated and untreated mice.[19] 
 More work still needs to be completed before AuNPs could be a robust and highly 
effective option for the treatment of cancer in the clinical setting.  The field of 
nanotechnology has made a significant amount of progress, but there are still many 
unanswered questions regarding the use of AuNPs for the treatment of cancer.  There is 
huge potential for the use nanoparticles in cancer therapy, and with the intense global 
interest in nanotechnology and nanomedicine; it is likely that many of these questions 











































































2.5 Cytotoxicity of Gold Nanoparticles  
Gold nanoparticles are intentionally engineered to interact with cells; therefore, it 
is important to ensure that these modifications do not cause any adverse effects in the 
body.  For biomedical purposes, especially in vivo applications, toxicity is a main factor 
to investigate when evaluating the potential and effectiveness of the nanomaterial.  
Cytotoxicity is one of the most common criteria used to assess the effects of the 
nanoparticles on cells and the particles viability for use within the body.  However, 
studies analyzing toxicities of AuNPs have a significant amount of uncertainty and are 
difficult to compare quantitatively.  The difficulty occurs because of variability in the 
type of nanoparticles, different size particles, different cell lines, concentration, exposure 
time, incubation time, and cytotoxicity assays used for the analyses.[3]  Despite these 
variables, there are trends that can be extracted and compared qualitatively from the 
many studies.   
One of the parameters many investigations have examined is the effect of size on 
the toxicity of the cell. A particular study performed by Coradeghini et.al. investigated 
mouse fibroblasts (3T3s) exposed to citrate stabilized AuNPs.[33]  The authors presented 
evidence that 5nm diameter citrate capped AuNPs were cytotoxic to the 3T3s at 
concentrations greater than 50 µM. Meanwhile, 3T3s exposed to 50, 100, 200, and 300 
µM of 15nm diameter citrate stabilized AuNPs had no indication of toxicity.[33]  Another 
study performed by Pernodet et. al. reported that 14nm diameter citrate capped AuNPs 
decreased cell proliferation and possessed slight signs of toxicity in human dermal 
fibroblasts.[9] The toxic effects observed in the study were attributed to actin stress. 
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However, a second, independent study performed by Li et.al. also reported the same 
effects in the presence of citrate-capped AuNPs with human lung fibroblasts, but the 
presented evidence actually indicated that cytotoxicity was a result of oxidative 
damage.[34]  Connor et al researched utilizing human leukemia cells (K562) with particle 
sizes ranging from 4 to 18 nm in diameter and surface modifiers of citrate, biotin, and 
cysteine, and glucose.  These cells showed no signs of toxicity at concentrations up to 
250 µM.[3],[35]   
Another study by Liu et. al. compared the effect of surface charge of AuNPs and 
the correlation it had with the cytotoxicity level. The results revealed that when using a 
MTT Cytotoxicity assay on HepG2 cells, positively charged 10-(mercaptodecyl)-
trimethyl-ammunium bromide (AuNP-TMA) exhibited higher cytotoxicity than the 
negatively charged 11-mercaptoundecaonic acid (AuNP-MUA).  Conversely, it was 
determined that negatively charged AuNP-MUA showed a higher cytotoxicity level than 
the positively charged AuNP-TMA in RAW 264.7 cells when using the same MTT assay.  
Utilizing a LDH assay indicated that a positively charged AuNP-TMA had a higher 
toxicity effect than the negatively charged AuNP-MUA in not only the HepG2 cells, but 
also the RAW 264.7 cells.[36]  The authors found in this study that toxicity did not show 
significant physiochemical property, such as size and surface functionality, dependence.  
Rather, this study indicated that cytotoxicity was more reliant on cell interactions with 
AuNPs between the two different cell lines and the type of colorimetric assay used to 
assess the cell viability.[36] 
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There exist many other cytotoxic studies examining the effects of size, shape, 
surface chemistry, uptake, concentration, colorimetric assayss, cell types, and culturing 
conditions.[3], [37]–[41]   Based on these current findings, the amount of cytotoxicity derived 
from the AuNPs versus other experimental variables and methods is unclear.  Thus, 
conflicting data exist with regard to the toxicity of AuNPs that requires further 
examination to fully understand the possible adverse effects from AuNPs.  
2.6 Conclusion 
In summary, AuNPs have emerged as a promising alternative or additive for 
many different biomedical applications, such as drug delivery, medical imaging, and 
cancer diagnosis and treatment.  Nanotechnology could also be a useful tool for other 
diseases such as Tuberculosis and Alzheimer’s. Further research to fully understand 
AuNPs and their effects within the human body, must be performed before clinical trials 
can occur.  Nevertheless, nanotechnology and its potential applications are expected to 
































Figure 3.1: The anatomical breakdown of the different layers of arteries, 
veins, and capillaries.  Blood vessels are made up of three different layers: 
tunica intima, tunica media, and tunica externa. Vascular smooth muscle 
cells (VSMCs) make up most of the tunica media in arteries and veins.[42]   
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3.1 Background of Vascular Smooth Muscle Cells 
The human body contains a vast network of blood vessels that delivers nutrients 
and oxygen throughout the body.  The vessels can be categorized into three different 
types of structures: arteries, veins, and capillaries.[42]  Arteries and veins are constructed 
out of layers.[42]  The innermost layer is the tunica intima, which is the main layer that is 
normally in contact with the blood.[42]  The tunica intima is composed of simple 
squamous epithelial cells (endothelium lining) and a sub-endothelial layer of connective 
tissue. The endothelium lining creates a smooth surface blood to flow without damage.[43]  
The middle layer of the blood vessel is called the tunica media.  The tunica media is 
comprised mostly of circularly arranged vascular smooth muscle cells (VSMCs), but 
other material such as collagen (type I, III, and V), elastin, and proteoglycans are also 
found in this layer.  The tunica media’s main function is to contract and relax the blood 
vessel walls to maintain steady blood flow. The outermost layer is the tunica externa or 
adventitia.  This layer is comprised mostly of loose connective tissue made up of type I 
collagen fibers and some elastin fibers. This outer layer assists in anchoring the vessels 
within the body and counteracts external forces, such as longitudinal stretching.[44]  All 
three layers shown in Figure 3.1 make up the arteries and veins in the cardiovascular 
system throughout the human body. 
Vascular smooth muscle cells are specialized cells designated to regulating the 
lumen diameter in blood vessels.  This diameter control dictates contraction and dilation 
of the vessel walls and determines the blood distribution and pressure throughout the 
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body.  Another special characteristics of VSMCs are that they are able to change their 
phenotype contractile or synthetic phenotype, between contractile or synthetic, in 
response to environmental factors. (see Figure 3.2) 
Normally, VSMCs in the tunica media express the contractile phenotype.  A 
significantly low rate of proliferation is exhibited and the cells express specific and 
unique contractile proteins.[45]  The other phenotype VSMCs can undergo change into is 
the synthetic or proliferative phenotype.  The synthetic phenotype expression is 
characterized by high proliferation rate, migration, and extra cellular matrix secretion, 
especially collagen type III and fibronectin.  This phenotype is typically expressed by the 
VSMCs in response to vascular injury and plays a vital role in vascular repair.  However, 
the downside to this phenotypic modulation or switching prompts the cells to respond to 
environmental signals readily leading to development of vascular diseases such as 
atherosclerosis, hypertension, and neointima formation. [34]  
3.2 Research Interest in Vascular Smooth Muscle Cells 
The ability of VSMCs to change their phenotype based on environmental stimulus 
plays a critical role in vascular repair.  Unfortunately, the altering phenotype 
characteristic is also a main factor in the development and progression of atherosclerosis. 
Researchers are beginning to better comprehend some of the molecular mechanisms and 
factors that controls transitions in the phenotypic state of the VSMCs, but little is known 
about what controls the etiology and advancement of the different stages of 
atherosclerosis.  Atherosclerosis is considered a chronic and complex disease that can 
ultimately result in the occlusion of the affected arteries and cause life-threatening 
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damage such as myocardial infarction or stroke.  This disease usually begins with some 
sort of endothelial dysfunction or damage, which allows for increase accumulation of 
plasma-derived lipids and their oxidation products into the matrix of the arterial wall.  
The intimal cells react by recruiting inflammatory cells to the site of injury, initiating the 
migration of monocytes into the vessel wall.  The monocytes become macrophages and 
ingest the oxidized lipid; thus, forming what many research call “foam cells”.  The 
recruitment of macrophages, and the production of inflammatory cytokines, oxygen free 
radicals, and other cascade factors lead to a downstream effect.  This chain of reactions 
induces the migration of the VSMCs from the medial layer into the intima layer.  The 
VSMCs begin to proliferate and synthesize matrix molecule to remodel the vascular wall 
a process also known as neointimal hyperplasia.  This process continues until the lumen 
of the blood vessels becomes increasingly occluded and eventually leads to a blockage of 
blood flow.[46], [47]  A schematic of the process of the development of atherosclerosis can 
be seen in Figure 3.3.   
Current treatment for atherosclerosis includes using grafts to bypass the area of 
blockage, or implanting a vascular stent to open up the occluded vessel.  However, these 
solutions possess unique complications and side effects.  There exist many current 
biomedical research projects focusing on the development of tissue-engineering blood 
vessels to try to combat this disease.  Emerging nanotechnology research aims to use 













 Vascular smooth muscle cells are important because they help blood vessels in the 
body to distribute and maintain a steady blood flow, that provides nutrients throughout 
the body.  VSMCs have the ability to change phenotype in response to different 
environmental stimuli such as mechanical or chemical factors to assist in maintaining a 
stable environment.  These cells also are significant in the development and progression 
of atherosclerosis.  Research with regards to VSMCs will further the understanding about 
the type of factors or even new materials such as nanoparticles, that will affect there 
phenotypic change and the ramifications these alterations will ultimately have on the 
body.   
Figure 3.2: Phenotypic modulation or switching of vascular smooth muscle cells.  The 
left side illustrates and list characteristic the characteristic of synthetic or proliferative 
phenotype.  The main feature to focus on is the lack contractile fibers, increase 
organelles for the production and secretion of extracellular matrix. The right side 
illustrates and list characteristic the characteristic of contractile phenotype. The main 
feature to notice is the abundance of contractile fibers spanning the cell body. [46] 
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Figure 3.3: Development of Atherosclerosis.  The disease begins with of 
damage to the endothelium lining or endothelial dysfunction.  The image shows 
different stage of the disease and what each stage looks like.  An important 
factor to notice is throughout the entire development and progression of 






THE EFFECTS OF DIFFERENT SIZE GOLD NANOPARTICLES ON THE 
MECHNICAL PROPERTIES OF VASCULAR SMOOTH MUSCLE CELLS 
UNDER PHYSIOLOGICAL STRESS 
 
4.1 Abstract: 
 Nanotechnology is an emerging and promising frontier for medicine and 
biomedical research due to its potential for applications such as drug delivery, imaging 
enhancement, and cancer treatment.  While these materials may possess significant 
possibilities, the effects of these particles in the body and how the particles affect the 
cells is not fully understood.  In this study, vascular smooth muscle cells (VSMCs) will 
be exposed to 5 and 20 nm diameter citrate AuNPs under mechanical conditions.  The 
cytotoxicity properties of these particles will be investigated using LDH and MTT assays.  
Atomic force microscopy will be used to study how the size of the nanoparticles affect 
the mechanical properties of the VSMCs.  Immunofluorescence staining for alpha actin 
will also be performed to enhance understanding of the phenotypic shift.  The LDH and 
MTT cytotoxicity assay results demonstrated that neither 5 nor 20 nm diameter 
nanoparticles are cytotoxic to the cells. However, the mechanical properties and cell 
morphology of the VSMCs was altered.  Under static conditions, both AuNP treatments 
decreased the mechanical properties of the cells.  The size of the nanoparticles had a 
softening effect on elastic modulus of the cell and sign of a synthetic phenotype was 
observed.  The VSMCs subjected to mechanical stretching exhibited higher elastic 
modulus compared to the static experimental groups.  Again, both AuNPs treatments 
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decreased the mechanical properties of the cells and signs of more synthetic phenotype 
was seen.  However, the size of the nanoparticles did not have any influence on cell’s 
elastic modulus unlike the static treated cells.  The mechanical testing condition provided 
a better look at how these particles would affect the cells in vivo.  While the nanoparticles 
are not cytotoxic to the VSMCs, they are altering the mechanical properties and 




 In recent decades, the use of nanoparticles, particularly the use of AuNPs has 
increased in biomedical research.  Their small size and unique properties allow these 
particles to interact with cellular components. Gold nanoparticle unique properties 
include: (a) wide variety of controllable sizes from 1 nm -100 nm, (b) Controlled shape 
variety, such as nanospheres and nanorods (c) large surface area to volume ratio, (d) 
functionalized readily with different conjugates.[2] All these properties can be engineered 
and altered depending on the particles intended application.  Thus, AuNPs provide a 
potential platform for development and application for the future of modern 
medicine.[4],  [6]–[8]  However, while nanotechnology has shown great promises, some 
biological effects of the nanoparticle and cellular interaction are not well understood.  
Some studies have shown adverse effects on the body as results of nanoparticles 
exposure. Understanding the interaction between the cell and the AuNPs will further the 
overall understanding of how to use these nanoparticles properly and how they can be 
applied in different biomedical applications, such as medical imaging, drug delivery, or 
tissue engineering.  Therefore, there is a need for the further investigation of the effects 
of these AuNPs on cellular functions.  
Vascular smooth muscle cells (VSMCs) play an important role in contracting and 
relaxing the blood vessel walls to control blood flow and pressure. They also play a 
critical role in vascular repair because of their unique capability to change phenotype 
when vascular injury or other environmental factors occurs.[46]–[48] As the field of 
nanotechnology moves into studying cardiovascular diseases[31], the understanding for 
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how these nanoparticles affects cells in the cardiovascular system is substantially more 
important.   
One of the most important effects to investigate is the cell toxicity level when 
exposed to these nanoparticles.  Many nanoparticle studies have investigated the potential 
cytotoxic effects of nanoparticles on various cell types.[3], [41], [49] However, there is not a 
large understanding of the toxic effects these particles have on VSMCs.  Common 
toxicity assays used include the Lactate Dehydrogenase (LDH) assay and MTT assay.  
The LDH assay is a colorimetric assay that measure cytotoxic level by measuring the 
plasma membrane integrity.  Lactate Dehydrogenase, which is a soluble cytosolic 
enzyme present in the cell, releases upon cell death due to damage to the plasma 
membrane damage. The MTT assay measures cytotoxic levels by quantifying the cell 
metabolic activity based on the ability of mitochondrial succinate/tetrazolium reductase 
system to convert the yellow dye (MTT) to purple formazan.  
Another interesting factor that will be examined in this study is how a dynamic in 
vitro testing condition will effect the mechanical properties of the cells, particularly 
VSMCs, compared to just a static experimental conditions.  Overall, there exist few 
studies that actually evaluate how these nanoparticles influence the cells under 
mechanical conditions.  The human body is not a static object.  The human body contains 
chemical stimulation and mechanical stimulation.  Investigating how these nanoparticle 
affects the VSMCs under mechanical conditions in vitro will help improve upon the 
understanding of the potential effects of these nanoparticle in vivo.  
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This study will evaluate how 5 nm and 20 nm diameter citrate capped AuNPs 
affect the mechanical properties of VSMCs under static and dynamic conditions, the 
cytotoxic effects on the cell, and phenotypic shift due to exposure to the nanoparticles. 
4.2 Material & Methods: 
Cell Culturing: 
Aortic VSMCs were isolated from adult Sprague Dawley rats.  The VSMCs were 
cultured in High Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) with 
10 % fetal bovine serum (FBS) (Sigma) and 1% antibiotic-antimycotic solution (Sigma). 
VSMCs were incubated in polystyrene T-75 flasks at 37°C and 5% CO2.  The cell culture 
media was replaced every 48 hours. They were grown to approximately 70-80% 
confluence in flasks.  Between passages, the cells were trypsinized with 0.25% trypsin 
with 0.02% ethyldiaminetetaacetic acid (Sigma).  Cells between passage 3 and 8 were 
used for experiments. 
Nanoparticles Synthesis: 
 The 5 nm diameter citrate capped spherical AuNPs were prepared by using100 µL 
of a 0.1 M citrate solution and 100 µL of 0.05 M of tetrachloroaurate (III) (HAuCl4).  The 
solution was next diluted in 20 mL of deionized water.  The aqueous gold/citrate mixture 
was then reduced by the addition of 100 µL of 0.05 M of sodium borohydride (NaBH4).  
This synthesis yielded a ruby red AuNP dispersion. 
 The 20 nm diameter citrate capped spherical AuNPs were prepared by adding 
500 µL of 0.05 HAuCl4 to 50 mL of deionized water. The solution was then heated.  
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Next, 1 mL of 0.1 M citrate solution was added.  This solution was stirred and heated for 
at least 10 minutes.  This synthesis method yielded a ruby red AuNP dispersion 
 Transmission Electron Microscopy (TEM) was performed to confirm the relative 
size of the nanoparticles.  
Flex Cell System: 
 The VSMCs were seeded into 6-well collagen plates (BioFlex) with 25,000 cells 
per well.  The cells were allowed to incubate over night to adhere to the plate.  For the 
static conditions and dynamic, 3 groups were made: control cells (CC), 5nm citrate 
capped gold nanoparticle (5AuNPs), and 20nm citrate capped gold nanoparticles group 
(20AuNP). These groups were also made for the dynamic conditions.  Once the cells 
were ready, 25 µM of phosphate buffered saline solution (PBS), Citrate solution, 5nm 
AuNPs, 20 nm AuNPs were added to the CC, CCS, 5 nm AuNP, and 20 nm AuNP group, 
respectively. To provide the dynamic condition, the Flex Cell 3000 System was used.  
The plates were loaded onto the platform and place inside the incubator.  The plates were 
pre-conditioned under 0-4 % cyclic strain at 0.1Hz for 30 minutes and 0-4% cyclic strain 
at 0.5 Hz for 30 minutes.  Finally, the groups were allowed to run for 72 hours under 0-
4% cyclic strain at 1.0 Hz.  
Cytotoxicity Assays: LDH 
The LDH assay kit used was CytoTox96® Non-Radioactive Cytotoxicity Assay 
(REF#: G1781 & G1782) purchased from Promega Corporation.  The VSMCs were 
seeded into a 96-well plate at 10,000 cells per well.  The cells were allowed to incubate 
over night to adhere to the cell plate.  The AuNPs were added at so that there were 5 µM, 
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25 µM, and 50  µM concentration in the experimental wells. Each sample group 
contained 6 wells.  After treatment period of 3 days, the lysis solution was added at a 
ratio of 15 µL per 100 µL of media.  Incubated the well with the lysis solution for 60 
minutes at 37°C and 5% CO2. Next, 50 µL of the supernatant of each of the wells were 
transferred to a new 96 well plate.  Then 50 µL of the reconstituted Substrate Mix was 
added to each well. The plate was covered and incubated at room temperature for 30 
minutes.  Finally, 50 µL of the Stop Solution was added to each well and the absorbance 
reading was taken at 490 nm. 
Cytotoxicity Assays: MTT 
The MTT assay kit used was CytoTox96® Non-Radioactive Cell Proliferation 
Assay (REF#: G4001 & G4002) purchased from Promega Corporation. The VSMCs 
were seeded into a 96-well plate at 10,000 cells per well.  The cells were allowed to 
incubate over night to adhere to the cell plate.  The AuNPs concentration were added at 
5  µM, 25 µM, and 50 µM to the experimental wells. Each sample group contained 6 
wells.  After a treatment period of 3 days,,15 µL of Dye Solution was added to each well.  
The plate was allow to incubate for 4 hours at 37°C and 5% CO2.  After the incubation 
period, the media/dye solution was removed and 100 µL of the Solubilization/Stop 
Solution was added to each well and the absorbance reading was taken at 570 nm. 
Immunofluorescence Staining: 
Immunofluorescence staining was performed to look at the smooth muscle alpha-
actin to see if there might be a phenotype change has occurred in the VSMCs based on 
the alpha acting concentration and distribution.   First, the cells were fixed in 4% 
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Paraformaldehyde for 10 minutes and then washed 3 times with PBS.  Next, the cells 
were then permeabilized with a solution of PBS/0.01M Glycine/0.2% Triton-X (Sigma) 
for 30 minutes.  Then, the cells were incubated in blocking solutions with 10% Goat 
Serum/PBS for 15 minutes. The cells were incubated with a dilution of 1:500 solution of 
Monoclonal Anti-Actin, Alpha-Smooth Muscle Antibody produced in Mice (Sigma 
Aldrich) with the blocking solution overnight at 4°C.  After the cells were incubated over 
night, the cells were washed with PBS 3 times.  Next, the cells were soaked in a dilution 
of 1:500 solution of Goat Anti-Mouse IgG(H+L) Fluorescein Conjugated Secondary 
Antibody (Millipore) with PBS for 2 hours protected from light.  After washing again 
with PBS 3 times, the cells were next stained with a SlowFade Gold anti-fade reagent 
with DAPI (Invitrogen).  The fluorescence images were taken using EVOS®FL Cell 
Imaging System (Life Technologies). 
Atomic Force Microscopy (AFM): 
Atomic Force Microscopy cytoindentation was performed on each sample 1- 24 
hours after the 72 hours of static and dynamic (Flexcell stretching) conditions.  The 
collagen membrane was carefully removed prior to testing and placed into a small AFM 
fluoro dish with 3 mL of new warm (37°C) media added into the dish.  For the AFM 
testing, the Asylum Research MFP-3D was operated in contact mode with a fluid cell.  A 
5 um diameter borosilicate spherical-tipped AFM probed with a spring constant of 
0.2 N/m was used to mechanically indent into each individual cells.  The AFM optical 
microscope (40x) was used to position the tip of the cantilever over the cell center of the 
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cell.  For each sample, every cell was indented 5 times to approximately 1 um depth to 
yield 5 force curves. 
Force Curve Analysis of Data: 
 The force curves were exported from the AFM software and a series of MATLAB 
scripts was utilized to analyze the data.  All MATLAB scripts used for the analyze in this 
experiment can be found in Appendix B.  Next, a contact point was established from the 
dataset at a displacement value where there is a rapid increase in the deflection. This 
quick increase indicated contact between the cell and the tip.  The offset for the deflection 
was adjusted in the MATLAB code.  After the adjustment, MATLAB measures the cell 
stiffness/the apparent elastic modulus of the cell was calculated by fitting the data to the 
Hertz Model.  The model was fitted to the first 100-200 nm of data.  The Hertz Model 











Figure 4.1 (Above): Hertz Model used for a spherical indenter. F and d 
represents the measured force and indentation depth respectively. The R 
represents the radius of the tip, which was set to 2.5 um.  The v 
represents the Poisson’s Ratio, which was set to 0.5. The variable E is 
the elastic modulus and the variable of interest in this equation.  
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Statistical Analysis: 
 A Student’s t-test was performed on the data to compare the control conditions to 
the experimental conditions to determine if any statistically significant differences existed 
between the samples.  A P-value of less than 0.05 was considered statistically significant. 
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4.3 Results: 




TEM was performed to confirm the relative size of the nanoparticle.  The image 
on the left in Figure 4.2 shows the 5 nm citrate capped AuNPs.  The sizes of these 
particles are relatively around 5nm.  The image on the right in Figure 4.2 shows the 
20 nm citrate capped AuNPs.  The sizes of these particles are relatively around 20 nm.   
 
Figure 4.2:  TEM image of the 5nm diameter (Left) and 20 nm diameter (Right) citrate 
capped AuNPs. 
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Figure 4.3: The results for the LDH Cytotoxicity on VSMCs treated 
with different concentrations of 5nm and 20nm citrate capped AuNPs. 
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The LDH Cytotoxicity results showed that VSMCs treated with 5 µM, 25 µM, 
and 50 µM of the 5nm AuNPs had a viability percentage of 98.68% ±2.72, 109.69% 
±2.43, and 115.84% ±1.82, respectively.  The 5 µM, 25 µM, and 50 µM of the 5nm 
AuNPs showed viability percentage of 116.60% ±5.61, 109.92% ±2.13, and 117.36% 
±2.14.  There were no adverse signs of cytotoxicity on the VSMCs under all the tested 
conditions.  Some of the groups showed a higher viability percentage than the control.  
  
 34 












Figure 4.4: The results for the MTT Cytotoxicity on VSMCs treated 
with different concentrations of 5nm and 20nm citrate capped AuNPs. 
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The MTT Cytotoxicity results showed similar trends to the LDH Cytotoxicity 
results. Again, no apparent cytotoxic effects were observed.  The VSMCs treated with 5 
µM, 25 µM, and 50 µM of the 5nm AuNPs had a viability percentage of 97.16% ±15.77, 
104.35% ±12.02, and 100.98% ±12.02, respectively.  The 5 µM, 25 µM, and 50 µM of 
the 5nm AuNPs showed viability percentage of 98.67% ±11.13, 100.21% ±14.47, and 
99.75% ±10.65.  There were no adverse signs of cytotoxicity on the VSMCs under all the 
tested conditions.   
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Immunofluorescence Staining: 





















Table 4.1: The alpha-actin fluorescence images of the VSMCs with static and 






 The VSMCs was stained to examine the alpha actin content to determine if a 
phenotypic shift occurred.  By looking at the actin distribution and arrangement using 
immunofluorescence staining, these phenotypic changes can be visually observed.  The 
VSMCs stained under the static conditions can be seen in Figure 5.1.A, 5.1.C, and 5.1.E.  
These VSMCs appear larger and shorter than the mechanical stretching/dynamic testing 
VSMCs, which indicates the synthetic phenotype expression.  The cells under the 
mechanical stretching shown in Figure 5.1.B, 5.1.D, and 5.1.F appear more elongated 
and thinner, a significant indication of a contractile phenotype expression.  Besides the 
shape and size of the VSMCs, the actin distributions of static and dynamic groups are 
also different.  The group subjected to mechanical stretching has a very neat and parallel 
arrangement of the actin fibers within the cell, and this ordered arrangement supports 
contractile phenotype characteristics.  The static condition cells do not show an ordered 
actin fiber orientation.  The actin fibers appear to be randomly arranged, indicating that 
these cells might be expressing more synthetic phenotype characteristics.  
Elastic Modulus from AFM Analysis: 
 The effects of the citrate capped AuNPs on the mechanical properties of the 
VSMCs can be seen from the elastic moduli results.  The control cells cultured under 
static conditions had an elastic modulus of 7.63±1.61 kPa.  When the VSMCs were 
treated with the 5 nm and 20 nm diameter citrate capped AuNPs, the elastic moduli of 
those cells were 5.72±1.46 kPa and 4.53±1.56 kPa, respectively.  Statistical analysis of 
the elastic moduli of the static experimental group showed a statistical significance 
(p<0.05) indicating there is a big change between the control and the experimental group.  
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There was a significant statistical difference between the control cells and the 
cells treated with both the 5 nm and 20 nm AuNPs.  The results showed that the 
nanoparticles had a softening effect on the mechanical properties of the cell.  There was 
also a significant statistical difference between the VSMCs treated with the 5 nm versus 
the 20 nm AuNPs.  This conclusion indicated that the increase in the size of the 
nanoparticles decreased the overall mechanical properties of the treated cells, at least for 
the static conditions.  The cells treated with the two different size AuNPs showed 
different effects.   
The controls cells subjected to mechanical stretching had an average elastic 
modulus around 11±1.10 kPa. The cells analyzed under mechanical stretching conditions 
were treated with 5 nm and 20 nm citrate capped AuNPs had elastic moduli of 
8.26±1.15 kPa and 8.53±1.93 kPa, respectively.  Statistical analysis showed there was 
only a significant statistical difference between the control cells and both nanoparticle 
treated group, but no significant difference between the 5 nm treated cells and the 20 nm 
treated cells.  These results indicated that the nanoparticles caused a decrease in the 
mechanical properties of the VSMCs regardless of static or dynamic testing conditions, 
but the effect of particle size on the mechanical properties of the cells was only seen 
under static testing conditions.  The elastic moduli of all the cells subjected to mechanical 
stretching were all significantly higher compared to the cells under the static 












Figure 4.5: The elastic modulus of the VSMCs under static condition. The data 
showed there is a significant difference between the control and the nanoparticle 
treated cells as well as directly between 5nm AuNP treated and the 20nm AuNP 








Figure 4.6: The elastic modulus of the VSMCs subjected to mechanical stretching 
condition. The data showed there is a significant difference between the control 
and the nanoparticle treated cells.  There is not a statistical difference the two 










Figure 4.7: Comparison of the elastic modulus from the static experimental 
groups to the dynamic experiment groups. The data showed that there is a 
significant difference between the dynamic cell groups and the static cell groups.  
The cells subjected to mechanical stretching had a higher elastic modulus.  
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4.4 Discussion: 
Based on the experimental results in this study, the 5 nm and 20 nm diameter 
citrate capped AuNPs do not appear to have any cytotoxic effects on the VSMCs.  Both 
the LDH and MTT cytotoxic results in this study are similar to other literature findings.  
However, even though the particles are not cytotoxic to the cells, they show some 
influence on the mechanical properties of the VSMCs.   Significant changes in the elastic 
moduli seen from the AFM results as well as the shift in morphology and alpha actin 
arrangement observed in the immunofluorescence staining, indicate that the AuNPs are 
decreasing mechanical properties and altering some of the characteristics of the VSMCs.   
This is a good indication of a phenotypic shift from a more contractile to a more synthetic 
expression. 
 The elastic moduli of the static versus dynamic groups showed that the VSMCs 
are more influenced by the nanoparticles under static conditions compared to dynamic 
stretching conditions.  The difference between the control cells under static condition and 
the AuNPs treated groups indicated that the nanoparticles decreased the mechanical 
properties of the cells.  The differences between the average elastic moduli of the 5 nm 
AuNP treated cells and the 20 nm AuNPs treated cells, suggested that the VSMCs 
exposed to larger particles have a slightly lower modulus of elasticity. The actin 
distribution and arrangement between the control and the static experimental groups also 
indicated a more synthetic phenotype due to the rounder cells and lack of orientation of 
the alpha-actin fibers.  See Figures 5.1.C and Figure 5.1.E.  
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  The cells subjected to mechanical stretching yielded similar results with a few key 
differences.  The elastic moduli of the dynamic control VSMCs group was significantly 
higher compared to both the AuNPs groups, but the change in the moduli based on 
nanoparticle size was not observed.  However, the effect on shape and size of the cells are 
still seen.  The VSMCs treated with AuNPs are apparently larger and rounder compared 
to the control group, which has more elongated cells.  The actin distribution and 
arrangement appeared similar between all the dynamic experimental groups.  The actin 
fiber seems to orient in a distinct direction.  This could be due to the presence of 
mechanical stimulation that can cause the ordering of the actin stress fiber in a certain 
direction.  
 Regarding the presence of mechanical stimulation, the AuNPs seems to be 
influencing the mechanical properties and overall morphology of the VSMCs.  This 
observation could indicate a potentially adverse effect if these nanoparticles change the 
VSMCs enough to alter the main cell function.  Another complication also arises because 
VSMCs play a critical role in the development and progression of atherosclerosis, and 
any alteration to the VSMCs could exacerbate or decrease atherosclerosis development.  
More testing needs to be performed to better understand the extent that the nanoparticles 
are affecting the cell morphology, mechanical properties, and overall function, and the 
ramifications these alterations have for cardiovascular diseases.  Knowing that the AuNPs 
are affecting the VSMCs furthers the understanding of the interactions between the 
nanoparticles and cells but also presents other challenges for scientists and researchers to 
address further.  
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4.5 Conclusion: 
Vascular smooth muscle cells exposed to citrate capped AuNPs cause changes in 
the cell morphology and decreased the mechanical properties of the cells, with or without 
mechanical stimulation.  The size of the AuNPs only influences the mechanical 
properties of VSMCs when the cells are under static conditions.  The nanoparticles are 
altering the alpha-actin formation within the cells.  Future research needs to investigate 
the intercellular processes and activities to further understand how the nanoparticles are 












RECOMMENDATION FOR FUTURE WORKS 
 
 The results in this study provide further insight into the world of nanoparticles 
and how they affect and interact with VSMCs.  This project could be improved upon by 
performing polymerase chain reaction (PCR) or Western Blotting targeting specific 
markers to gather more evidence of phenotypic change due to the exposure of particles.  
This study could also be repeated with a larger range of particle sizes, such as 2 nm, 
15 nm, 30 nm, and 50 nm, to further confirm and understand the effect of particle size on 
the VSMCs. 
 One of the main questions instigated by this study was where are these 
nanoparticles depositing once they are inside the cell?  Some literary papers have 
reported that the nanoparticles are trapped in vesicles within the cells and others 
suggested the nanoparticle are able to interact freely with substances in the cytoplasm. 
Transmission electron microscopy or dual-photon microscopy techniques could be 
performed to analyze the ultimate location of nanoparticles within the cells.  
Understanding the nanoparticles location within the cell could provide a better 
comprehension and prediction of possible effects these particles could be having on the 
cell.  
 Another direction to take this research is to investigate how the exposure of these 
nanoparticles affects a co-culture of vascular endothelial cells (VECs) and vascular 
smooth muscle cells (VSMCs) cultured together.  The novelty of this research is that the 
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investigation will utilize two cell lines compared to just one cell type, and this will 
simulate a more in vivo like environment.  The study would look at the not only the 
nanoparticles and the VSMCs interaction, but also the interaction between the 
nanoparticles and the VECs as well as the VECs and the VSMCs.  The results would 
provide a greater insight into the nanoparticles effects on the blood vessels in vivo using 















Isolating Vascular Smooth Muscle Cells 
 
• Sacrifice rat using CO2 asphyxiation and cervical dislocation 
• Remove aorta from subclavian origin to the diaphragm bifurcation and place in 
DMEM with pen/strep 
• Use tissue culture hood to remove all adventitia and connective tissue.  All adventitia 
must be removed to ensure you only attain VSMCs 
• Cut vessel longitudinally so it lays flat and scrape off endothelium gently with scalpel 
blade and rinse thoroughly in DMEM with pen/strep 
• Cut the vessel into ~5 mm squares and place them in digestion solution that includes 
5 ml DMEM, pen/strep (1%), Collagenase type II (final concentration 175U/ml), and 
10% FBS for 20 minutes 
• Centrifuge at 500 rpm for 1 minute and remove the supernatant and wash the pellet 
with DMEM containing pen/strep 
• Resuspend the pieces in another digestion solution containing DMEM, pen/strep (1%) 
Collagenase type II (final concentration 175U/ml), Elastase type III (final 
concentration 0.25 mg/ml) and 10% FBS for 1 hour.  Be sure to shake the tube gently 
every 10 minutes until the vessel is gossamer thin.  When the vessels are dissolved 
stop the digestion by diluting with equal volume of DMEM with pen/strep and 20% 
FBS 
• Centrifuge 1000 rpm for 5 minutes and remove the supernatant 
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• Suspend cells in DMEM with pen/strep and 20% FBS and place in T-25 flask and put 
in incubator (37C, 5% CO2).  Don’t change media for 72 hours as cells need 
sufficient time to adhere to flask.  
• Maintain the cells using DMEM with 20% FBS and pen/strep until cells reach P4 
then use 10% FBS 
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Appendix B 
MATLAB Script for AFM Analysis 
Hertz Model Analysis for Batch Export from MFP3-D AFM machine (reads text files 
generated by the computer) 
function elasticity = massexcompile(folderin) 
mainfolder = cd 
format long 
fnames = dir(folderin); 
numfids = length(fnames); 
cd(folderin); 
%filtering out irrelevent "files" such as '.' and '..' 
cellnames = {}; 
for c = 1:numfids; 
    if 'C' == fnames(c).name(1) % 'C' represents the letter that the 
relevent file names begin with 
        cellnames{end+1} = fnames(c).name; 
    end 
end 
%combine every 3 files and write 
counter = 1; 
numcell = length(cellnames); 
numfile = 1; 
elasticity = []; 
  
% OMIT THIS WHILE LOOP IF YOU WANT TO LOAD CELLS INDIVIDUALLY 
while counter <= numcell 
    a = load(cellnames{counter}); 
    c = load(cellnames{counter+2}); 
     
    cd(mainfolder); 
    elasticity(end+1,[1,2]) = elast_analysis(c,a,mainfolder); 
    counter = counter+3; 
    cd(folderin); 




function e = elast_analysis(c,a,mainfolder) 
cd(mainfolder) 
format long 
k = 0.1416; %spring constant value N/m 
v = 0.5; %poisson's ratio 
R = 2.5*10^-6;  % tip radius in meters 
L = 10*10^-9 ;     %lower bound for elasticity (in m from contact 
point) 





ak = a.*k; 
%filter deflection values 
d = AFM_butter(ak); 
%Separation of extension and retraction 
l = floor(length(c)/2); 
xe = c(200:l);% add 200 in order to omit first several data points 
(irratic behavior due to filtering 
ye = d(200:l); 
if rem(length(c),2)==0; 
    xr = c(end-200:-1:l+1); % subtract 200 in order to omit first 
several data points 
    yr = d(end-200:-1:l+1); 
    else 
    xr = c(end-200:-1:l+2); 
    yr = d(end-200:-1:l+2); 
end 
  
%correct x,y offsets 
[xe,ye] = xycorrect(xe,ye); 
[xr,yr] = xycorrect(xr,yr); 
   
format long; 
erange = []; 
for i = [1:1:length(xe)]; 
    if xe(i)>=L && xe(i)<=U; 
        erange(end+1) = i; 
    end; 
end; 
rrange = []; 
for i = [1:1:length(xr)]; 
    if xr(i)>=L && xr(i)<=U; 
        rrange(end+1) = i; 








e = [emodulus, rmodulus]; 
 









function [xc,yc] = xycorrect(x,y) 
s = 0.002; %slope sensitivity 
  
  
%correction for y 
format long 
region = [1:length(x)/4]; 
slope = polyfit(x(region),y(region),1); 
yci = y-(slope(1).*y); 
  
%correction for x 
numslope = diff(yci)./diff(x); 
index = 1; 
condition = 0; 
contactx = 0; 
while condition == 0 && index ~= length(numslope) 
    if numslope(index) > s && mean(numslope(index:5:index+200)) > s; 
        condition = 1; 
        contactx = index; 
    end 
    index = index+1; 
end 
xc = x-x(contactx); 
  
% correct again for y 
yc = yci-yci(contactx); 
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